TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06800963: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Sponsor: ImmunityBio, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,072,360

Rescue Site Savings

+$705,500

Unlock Full NCT06800963 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06800963 Rescue Dossier →